You are here

obesity

Lilly shares fall as obesity drug sales miss forecasts

BioPharma Dive

Wed, 10/30/24 - 11:52 am

Weight-loss drugs didn't curb health costs within two years

Reuters

Thu, 10/24/24 - 11:11 am

Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market

Reuters

Thu, 10/24/24 - 09:53 am

1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move

Motley Fool

Thu, 10/17/24 - 09:24 am

Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.

BioPharma Dive

Fri, 10/11/24 - 11:10 am

Skye Bioscience

Medicare coverage of weight loss drugs would cost $35B: CBO

The Hill

Wed, 10/9/24 - 08:56 pm

Weight loss gold rush: Developers vie for next blockbuster treatment

Pharmaphorum

Tue, 10/8/24 - 09:45 am

Boehringer Ingelheim

Scholar Rock scores with ‘surprise’ success in SMA drug study

BioPharma Dive

Mon, 10/7/24 - 11:52 am

spinal muscular atrophy

Weight Loss From GLP-1 Drugs Not As Robust In Real-World Settings

Forbes

Wed, 10/2/24 - 11:20 am

Kailera launches with $400M series A and clutch of Chinese obesity drugs

Fierce Biotech

Tue, 10/1/24 - 09:57 am

Kailera Therapuetics

Cerevel Therapeutics

Rivus reveals data to back up muscle-sparing claims of phase 2 obesity drug

Fierce Biotech

Mon, 09/30/24 - 08:38 pm

Rivus Pharmaceuticals

clinical trials

Roche targets more than $3 billion in annual obesity sales

Reuters

Mon, 09/30/24 - 10:09 am

Carmot Therapeutics

BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials

Fierce Biotech

Wed, 09/25/24 - 11:48 am

Inside the GLP-1 'price war'

Beckers Hospital Review

Tue, 09/24/24 - 11:52 am

Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand

Clinical Trials Arena

Tue, 09/24/24 - 11:51 am

Arrowhead Pharmaceuticals

clinical trials

Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M

Fierce Biotech

Mon, 09/23/24 - 11:33 am

Ventyx Biosciences

Parkinson's Disease

Novo obesity prospect linked to ‘mild to moderate neuropsychiatric side effects’ in phase 2

Fierce Biotech

Fri, 09/20/24 - 11:30 am

clinical trials

EU regulator backs use of Novo's Wegovy for obesity-related heart condition

Reuters

Thu, 09/19/24 - 09:16 pm

heart failure with preserved ejection fraction

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

CNBC

Thu, 09/19/24 - 11:13 am

Obesity pill race heats up as Novo, Roche and Terns share data

BioSpace

Tue, 09/17/24 - 11:22 am

Terns Pharmaceuticals

clinical trials

Pages